Ovarian Cancer Awareness: Why CA 125 Testing and Laboratory Quality Matter in Diagnosis and Monitoring

In  the UK, March marks Ovarian Cancer Awareness Month, and each year on the 8th May, healthcare organisations all over the world also observe World Ovarian Cancer Day. While these initiatives focus on symptom recognition and early detection, for the laboratory, the challenge lies in providing the analytical precision required to support early intervention and long-term monitoring.

Launched in 2013 by a coalition of international ovarian cancer advocacy groups, World Ovarian Cancer Day was created to unite organisations and individuals in raising awareness, promoting earlier detection, and improving outcomes for those affected by the disease. For laboratories, this awareness serves as a reminder that high-quality diagnostics underpin every stage of the patient pathway.

Key Takeaways: Precision in Ovarian Cancer Diagnosis

• Early detection remains a central goal of ovarian cancer awareness initiatives, particularly given the non-specific nature of symptoms.
• Measuring the CA 125 level is a cornerstone of oncology quality testing, used to investigate suspected pathology and monitor treatment response.
• Because clinical decisions are based on subtle shifts in tumour markers, participation in Oncology EQA Programmes is essential to eliminate analytical drift and ensure results reflect patient biology.
• Beyond the lab, resources like UK NEQAS IIA’s Digital Academy help professionals stay updated on evolving diagnostic interpretations.

The Analytical Complexity of Ovarian Cancer Diagnostics

Ovarian cancer is sometimes referred to as a ‘silent’ disease, not because it lacks symptoms, but because those symptoms are frequently vague and often overlap with benign conditions. This diagnostic ambiguity places additional responsibility on laboratory investigations to provide dependable biochemical data.

For this reason, diagnosis and monitoring often rely on a combination of clinical evaluation, imaging, and laboratory testing. No single test confirms ovarian cancer on its own, but together, laboratory markers can provide important information that guides clinical decision-making.

The Role of CA 125 in Ovarian Cancer

One of the most established tumour markers used in ovarian cancer management is CA 125. Within oncology diagnostics, tumour marker EQA schemes help laboratories monitor performance across analytes.

Measurement of the CA 125 level in serum may support:

• Investigation of suspected ovarian pathology
• Monitoring response to treatment
• Detecting disease recurrence
• Long-term clinical management

It is important to note that CA 125 is not specific to ovarian cancer and may be elevated in other benign or inflammatory conditions. Its clinical value lies not only in a single result, but often in trends over time.

Because treatment decisions may be influenced by relatively small changes in CA 125 level, analytical consistency is essential. A variation that reflects methodological inconsistency rather than biological change could potentially influence clinical interpretation.

Why Oncology Quality Testing Matters

This is where laboratory quality processes become critical. In oncology diagnostics, tumour marker testing must be accurate, reproducible, and comparable across laboratories and platforms.

In the measurement of CA 125 levels, inter-assay variability remains a significant challenge. Differences in antibody specificity and calibration across various platforms mean that a 'stable' patient could show a fluctuating CA 125 level simply by switching between laboratories or methodologies. Structured oncology quality assessment testing through EQA Providers such as UK NEQAS IIA provides the cross-platform insight needed to mitigate these risks, and ensures that laboratories can identify variability, monitor performance, and maintain confidence in reported results.

Reliable quality systems help ensure that when a CA 125 level changes, the result reflects patient biology, not analytical drift.

How External Quality Assessment Strengthens Confidence

External quality assessment (EQA) provides laboratories with an independent mechanism to evaluate performance against peer institutions. Through participation, laboratories can:

• Benchmark their CA 125 measurement performance
• Assess method-specific variation
• Monitor long-term analytical trends
• Support accreditation and governance requirements

In the context of ovarian cancer awareness, this may seem indirect, but it is fundamental. Public campaigns encourage earlier detection and better care, and robust laboratory performance helps ensure that the results informing those decisions are reliable.

Laboratories measuring tumour markers such as CA 125 can explore UK NEQAS IIA’s dedicated Oncology EQA Programmes to understand how structured performance assessment supports consistent and reliable reporting.

Education, Interpretation, and Continuous Improvement

Maintaining high standards in tumour marker testing extends beyond analytical performance alone. Interpretation, understanding assay limitations, and awareness of emerging methodologies are equally important.

Educational initiatives and professional development resources, including materials available through our Digital Academy, can help laboratories remain aligned with evolving practice in oncology diagnostics and strengthen confidence in clinical reporting.

Ovarian Cancer Awareness: The Laboratory’s Essential Role

During Ovarian Cancer Awareness Month in March and on World Ovarian Cancer Day on 8th May, attention is rightly focused on patients, advocacy, and improved survival. Behind every diagnostic pathway, however, is a laboratory result.

Accurate CA 125 testing, supported by strong quality processes and continuous evaluation, plays an important role in helping clinicians make informed decisions. Awareness campaigns highlight the importance of early detection; laboratory quality helps ensure that detection and monitoring are built on dependable data.

Laboratories involved in tumour marker testing can learn more about our Oncology EQA Programmes or explore the Digital Academy to access educational resources that support continuous improvement in oncology diagnostics.

Ovarian cancer awareness is not only about recognising symptoms, but also about ensuring the systems that support diagnosis are robust, consistent, and clinically reliable.